NCT07244705 2025-11-24A Study of ABT-301 Plus Tislelizumab With Bevacizumab in pMMR/Non-MSI-H Locally Advanced or mCRCAnbogen Therapeutics, Inc.Phase 1/2 Recruiting66 enrolled